2′-Fluoro-6′-Methylene Carbocyclic Nucleosides for Resistant HBV
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current antiviral therapies for Hepatitis B virus (HBV) face challenges with drug-resistant mutants, leading to reduced efficacy and increased risk of viral relapse upon treatment discontinuation, necessitating long-term therapy and resulting in mitochondrial toxicity and liver deterioration.
Innovation Solution
Development of 2′-Fluoro-6′-methylene carbocyclic nucleosides, particularly 2′-Fluoro-6′-methylene carbocyclic adenosine (FMCA) and its monophosphate prodrug, which exhibit potent activity against wild-type HBV and drug-resistant mutants, including lamivudine and adefovir-resistant strains, through specific binding mechanisms and reduced mitochondrial toxicity.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If current nucleoside/nucleotide analogs are used for long-term HBV treatment, then viral replication is suppressed, but drug-resistant mutants emerge reducing treatment efficacy
Solution Approach 1:
The patent applies parameter changes by modifying the chemical structure of nucleoside analogs through fluorine substitution at the 2′ position and methylene group addition at the 6′ position of the carbocyclic ring. These structural parameter changes create novel compounds (2′-fluoro-6′-methylene carbocyclic nucleosides) that maintain antiviral activity while overcoming resistance to existing drugs like lamivudine and adefovir, thereby resolving the contradiction between treatment efficacy and drug resistance
Solution Approach 2:
The invention creates composite molecular structures by combining fluorinated carbocyclic sugar moieties with nucleobases, forming hybrid nucleoside analogs that integrate properties of both natural nucleosides and synthetic fluorinated compounds. This composite approach enables the drugs to maintain affinity for viral polymerase while evading resistance mechanisms, thus preserving treatment efficacy against drug-resistant mutants
2Duration of action of stationary object
If long-term nucleoside/nucleotide treatment is administered, then viral relapse is prevented, but mitochondrial toxicity and liver deterioration occur
Solution Approach 1:
The patent employs parameter changes by introducing fluorine atoms and methylene groups into the nucleoside structure, which alters the metabolic pathway and reduces mitochondrial toxicity. The 2′-fluoro-6′-methylene carbocyclic structure modifies how the drug is processed by cellular enzymes, thereby maintaining long-term antiviral activity while minimizing harmful effects on mitochondrial function and liver health during extended treatment periods
Data Source
AI summary
The present invention relates to 2′-Fluoro-6′-methylene carbocyclic nucleosides, pharmaceutical compositions containing these nucleosides and their use in the treatment or prophylaxis of a number of viral infections and secondary disease states and conditions thereof, especially including Hepatitis B virus (HBV) and secondary disease states and conditions thereof (cirrhosis and liver cancer), Heptatitis C virus (HCV), Herpes Simplex virus I and II (HSV-1 and HSV-2), cytomegalovirus (CMV), Varicella-Zoster Virus (VZV) and Epstein Barr virus (EBV) and secondary cancers which occur thereof (lymphoma, nasopharyngeal cancer, including drug resistant (especially including lamivudine and/or adefovir resistant) and other mutant forms of these viruses.